Our New Website Is Here!
As part of our merger with St. Paul Research, we’ve created a new website that will house all of our collective content under one roof, bringing you a higher level of research and service through our analysts’ combined insight, expertise, and perspective. Go to my.stpaulresearch.com to access our new site.

We Tapped Ray’s Private Phone Line…

Aaron Gentzler: Hi, everyone. Welcome to an exclusive Technology Profits Daily briefing. I’m Aaron Gentzler, your publisher at Seven Figure Publishing.

With me today is Ray Blanco, chief tech expert and lead analyst here at Seven Figure Publishing. Hi, Ray. How are you?

Ray Blanco: Doing great.

Aaron Gentzler: Today, Ray, we’re going to talk about the mega profit pipeline, aka the blockbuster biotech trends that could power folks to incredible new levels of wealth.

You ready to go?

Ray Blanco: Let’s roll.

Ray Blanco: One of the most exciting stories coming from the biotech space right now is the amazing uses of cannabinoid based drugs, i.e. medical marijuana.

One of the newest ways cannabinoids (CBDs) are being used is for gastrointestinal ailments like Crohn’s disease. In my research, I’ve found some great leads on a few companies that are tackling this problem head-on, and we could see some actionable news coming very soon in Q3.

My own idea is that CBDs don’t just block pain from Crohn’s disease, I think the anti-inflammatory properties of CBDs are playing a big part in solving the Crohn’s disease problem. And this discovery could mean new, beneficial therapies on several levels.

Aaron Gentzler: Absolutely. Now is the pain of Crohn’s disease unique in any way, or could a cannabinoid drug, if continued to be developed, work for pain management in other ailments too?

Ray Blanco: Well, we don’t know if that will be the case for sure, but we already know a lot about cannabinoids and how people can use them to manage pain. This could offer new ways to combat the opioid crisis. And hopefully this new wave of Crohn’s treatments will have enough data compiled to make additional headway into other areas of pain management.

Aaron Gentzler: That’s a great assessment Ray, thanks. I really like the all of the above approach. As you described it, they’re multiple opportunities to come up with something with huge here.

Ray Blanco: Thanks Aaron. But before we wrap things up I do want to touch on another groundbreaking therapy in development for Cystic Fibrosis.

CF is a genetic disease. There’s different variants of Cystic Fibrosis, but the essential problem is that chlorides don’t get transported across the cell membranes properly. One of the hallmarks of CF is the massive accumulation of mucus in the lungs, which eventually gets infected, creating all kinds of lung problems. And CF is a killer. People with CF don’t live long.

Now, one of the big, big success stories in CF has been Vertex (NASDAQ: VRTX). They created the first great CF therapy that actually attacked the root cause of the disease.

But Vertex is far from done battling CF. Earlier this week the company announced FDA approval for its newest CF drug, Kalydeco, for expanded use in children aged 12 months to two years. And according to Yahoo Finance: “A similar line-extension application is under review in the EU with a decision expected in the first half of next year.”

Aaron Gentzler: Huge potential.

Ray Blanco: Indeed.

Aaron Gentzler: Well said Ray. I think that’s a good spot to end things today. Thanks again. Great stuff as always. We’ll talk again soon

Ray Blanco: Thanks.

For Technology Profits Daily,

Ray Blanco
Chief Technology Expert, Technology Profits Daily

You May Also Be Interested In:

Ray Blanco

Ray Blanco is the editor of Technology Profits Confidential as well as Breakthrough Technology Alert, FDA Profit Alert, and Technology Profits Daily. Ray has been with Seven Figure Publishing since 2010. In 2019, his closed positions in Technology Profits Confidential outperformed the S&P500 by 50%.

View More By Ray Blanco